Literature DB >> 31761657

Inhibition of hedgehog signaling by stereochemically defined des-triazole itraconazole analogues.

Jiachen Wen1, Kelly A Teske1, M Kyle Hadden2.   

Abstract

Dysregulation of the hedgehog (Hh) signaling pathway is associated with cancer occurrence and development in various malignancies. Previous structure-activity relationships (SAR) studies have provided potent Itraconazole (ITZ) analogues as Hh pathway antagonists. To further expand on our SAR for the ITZ scaffold, we synthesized and evaluated a series of compounds focused on replacing the triazole. Our results demonstrate that the triazole region is amenable to modification to a variety of different moieties; with a single methyl group representing the most favorable substituent. In addition, nonpolar substituents were more active than polar substituents. These SAR results provide valuable insight into the continued exploration of ITZ analogues as Hh pathway antagonists.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hedgehog pathway; Itraconazole; Structure-activity relationship

Year:  2019        PMID: 31761657      PMCID: PMC6942223          DOI: 10.1016/j.bmcl.2019.126794

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

1.  Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.

Authors:  Wei Shi; Benjamin A Nacev; Blake T Aftab; Sarah Head; Charles M Rudin; Jun O Liu
Journal:  J Med Chem       Date:  2011-10-05       Impact factor: 7.446

Review 2.  Structure-brain exposure relationships.

Authors:  Stephen A Hitchcock; Lewis D Pennington
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

3.  Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia.

Authors:  Antonis Dagklis; Daphnie Pauwels; Idoya Lahortiga; Ellen Geerdens; Emilie Bittoun; Barbara Cauwelier; Thomas Tousseyn; Anne Uyttebroeck; Johan Maertens; Gregor Verhoef; Peter Vandenberghe; Jan Cools
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

4.  Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.

Authors:  Jennifer R Pace; Kelly A Teske; Lianne Q Chau; Radha Charan Dash; Angela M Zaino; Robert J Wechsler-Reya; M Kyle Hadden
Journal:  J Med Chem       Date:  2019-04-05       Impact factor: 7.446

5.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Authors:  James Kim; Jean Y Tang; Ruoyu Gong; Jynho Kim; John J Lee; Karl V Clemons; Curtis R Chong; Kris S Chang; Mark Fereshteh; Dale Gardner; Tannishtha Reya; Jun O Liu; Ervin H Epstein; David A Stevens; Philip A Beachy
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

6.  Repurposing itraconazole as an anticancer agent.

Authors:  Hiroshi Tsubamoto; Tomoko Ueda; Kayo Inoue; Kazuko Sakata; Hiroaki Shibahara; Takashi Sonoda
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

7.  Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Authors:  Michael R Savona; Daniel A Pollyea; Wendy Stock; Vivian G Oehler; Mark A Schroeder; Jeffrey Lancet; James McCloskey; Hagop M Kantarjian; Weidong Wendy Ma; M Naveed Shaik; A Douglas Laird; Mirjana Zeremski; Ashleigh O'Connell; Geoffrey Chan; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

8.  Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.

Authors:  Kelly A Teske; Radha Charan Dash; Shana R Morel; Lianne Q Chau; Robert J Wechsler-Reya; M Kyle Hadden
Journal:  Eur J Med Chem       Date:  2018-11-23       Impact factor: 6.514

Review 9.  Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.

Authors:  Mohd Wahid; Arshad Jawed; Raju K Mandal; Sajad A Dar; Saif Khan; Naseem Akhter; Shafiul Haque
Journal:  Crit Rev Oncol Hematol       Date:  2015-11-21       Impact factor: 6.312

10.  Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.

Authors:  Melissa A Burns; Zi Wei Liao; Natsuko Yamagata; Gayle P Pouliot; Kristen E Stevenson; Donna S Neuberg; Aaron R Thorner; Matthew Ducar; Emily A Silverman; Stephen P Hunger; Mignon L Loh; Stuart S Winter; Kimberly P Dunsmore; Brent Wood; Meenakshi Devidas; Marian H Harris; Lewis B Silverman; Stephen E Sallan; Alejandro Gutierrez
Journal:  Leukemia       Date:  2018-03-20       Impact factor: 11.528

View more
  2 in total

Review 1.  Medulloblastoma drugs in development: Current leads, trials and drawbacks.

Authors:  Jiachen Wen; M Kyle Hadden
Journal:  Eur J Med Chem       Date:  2021-02-08       Impact factor: 6.514

2.  N-Phenacyldibromobenzimidazoles-Synthesis Optimization and Evaluation of Their Cytotoxic Activity.

Authors:  Anna Kowalkowska; Konrad Chojnacki; Maciej Multan; Jan K Maurin; Edyta Łukowska-Chojnacka; Patrycja Wińska
Journal:  Molecules       Date:  2022-07-07       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.